FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Published at www.nejm.org November 10, 2003 (10.1056/NEJMoa032292)

	PDF Supplementary Material Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Angiotensin-converting-enzyme (ACE) inhibitors such as captopril reduce mortality and cardiovascular morbidity among patients with myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. In a double-blind trial, we compared the effect of the angiotensin-receptor blocker valsartan, the ACE inhibitor captopril, and the combination of the two on mortality in this population of patients.

Methods Patients receiving conventional therapy were randomly assigned, 0.5 to 10 days after acute myocardial infarction, to additional therapy with valsartan (4909 patients), valsartan plus captopril (4885 patients), or captopril (4909 patients). The primary end point was death from any cause.

Results During a median follow-up of 24.7 months, 979 patients in the valsartan group died, as did 941 patients in the valsartan-and-captopril group and 958 patients in the captopril group (hazard ratio in the valsartan group as compared with the captopril group, 1.00; 97.5 percent confidence interval, 0.90 to 1.11; P=0.98; hazard ratio in the valsartan-and-captopril group as compared with the captopril group, 0.98; 97.5 percent confidence interval, 0.89 to 1.09; P=0.73). The upper limit of the one-sided 97.5 percent confidence interval for the comparison of the valsartan group with the captopril group was within the prespecified margin for noninferiority with regard to mortality (P=0.004) and with regard to the composite end point of fatal and nonfatal cardiovascular events (P<0.001). The valsartan-and-captopril group had the most drug-related adverse events. With monotherapy, hypotension and renal dysfunction were more common in the valsartan group, and cough, rash, and taste disturbance were more common in the captopril group.

Conclusions Valsartan is as effective as captopril in patients who are at high risk for cardiovascular events after myocardial infarction. Combining valsartan with captopril increased the rate of adverse events without improving survival.

Notice: This article was published at www.nejm.org on November 10, 2003, to coincide with a presentation at the annual meeting of the American Heart Association. It will appear in the November 13, 2003, issue of the Journal.

Click on "PDF of this article" for the full text.

This article has been cited by other articles:

• Wilson, J M (2009). Diagnosis and treatment of acquired coronary artery disease in adults. Postgrad. Med. J. 85: 364-365 [Abstract] [Full Text]  
• Moukarbel, G. V., Signorovitch, J. E., Pfeffer, M. A., McMurray, J. J. V., White, H. D., Maggioni, A. P., Velazquez, E. J., Califf, R. M., Scheiman, J. M., Solomon, S. D. (2009). Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. Eur Heart J 0: ehp256v1-ehp256 [Abstract] [Full Text]  
• Berry, C., Pieper, K. S., White, H. D., Solomon, S. D., Van de Werf, F., Velazquez, E. J., Maggioni, A. P., Califf, R. M., Pfeffer, M. A., McMurray, J. J.V. (2009). Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). Eur Heart J 30: 1450-1456 [Abstract] [Full Text]  
• Elijovich, F., Laffer, C. (2009). A role for single-pill triple therapy in hypertension. Ther Adv Cardiovasc Dis 3: 231-240 [Abstract]  
• Parving, H.-H., Brenner, B. M., McMurray, John. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Ghadanfar, M., Weissbach, N., Xiang, Z., Armbrecht, J., Pfeffer, M. A. (2009). Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 24: 1663-1671 [Abstract] [Full Text]  
• White, M., Ross, H., Levesque, S., Whittom, L., Pelletier, G. B, Racine, N., Meloche, S., Voisin, L. (2009). Effects of Angiotensin-Converting Enzyme Inhibitor Versus Valsartan on Cellular Signaling Events in Heart Transplant. The Annals of Pharmacotherapy 43: 831-839 [Abstract] [Full Text]  
• Tian, Q., Miyazaki, R., Ichiki, T., Imayama, I., Inanaga, K., Ohtsubo, H., Yano, K., Takeda, K., Sunagawa, K. (2009). Inhibition of Tumor Necrosis Factor-{alpha}-Induced Interleukin-6 Expression by Telmisartan Through Cross-Talk of Peroxisome Proliferator-Activated Receptor-{gamma} With Nuclear Factor {kappa}B and CCAAT/Enhancer-Binding Protein-{beta}. Hypertension 53: 798-804 [Abstract] [Full Text]  
• Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., Oates, J. A., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W. (2009). 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53: e1-e90 [Full Text]  
• Jessup, M., Abraham, W. T., Casey, D. E., Feldman, A. M., Francis, G. S., Ganiats, T. G., Konstam, M. A., Mancini, D. M., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W. (2009). 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53: 1343-1382 [Full Text]  
• 2009 WRITING GROUP TO REVIEW NEW EVIDENCE AND UPDA, , Jessup, M., Abraham, W. T., Casey, D. E., Feldman, A. M., Francis, G. S., Ganiats, T. G., Konstam, M. A., Mancini, D. M., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W. (2009). 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation 119: 1977-2016 [Full Text]  
• 2005 WRITING COMMITTEE MEMBERS, , Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., Oates, J. A., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W. (2009). 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation 119: e391-e479 [Full Text]  
• Mollmann, H., Nef, H., Elsasser, A., Hamm, C. (2009). Stem cells in myocardial infarction: from bench to bedside. Heart 95: 508-514 [Full Text]  
• Onuigbo, M.A.C. (2009). Reno-prevention vs. reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ontarget--a call for more circumspection. QJM 102: 155-167 [Abstract] [Full Text]  
• Lee, B.-C., Hsu, H.-C., Tseng, W.-Y. I., Chen, C.-Y., Lin, H.-J., Ho, Y.-L., Su, M.-J., Chen, M.-F. (2009). Cell therapy generates a favourable chemokine gradient for stem cell recruitment into the infarcted heart in rabbits. Eur J Heart Fail 11: 238-245 [Abstract] [Full Text]  
• Hawkins, N. M., Huang, Z., Pieper, K. S., Solomon, S. D., Kober, L., Velazquez, E. J., Swedberg, K., Pfeffer, M. A., McMurray, J. J.V., Maggioni, A. P., for the Valsartan in Acute Myocardial Infarction T, (2009). Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail 11: 292-298 [Abstract] [Full Text]  
• Tsagalis, G., Akrivos, T., Alevizaki, M., Manios, E., Theodorakis, M., Laggouranis, A., Vemmos, K. N. (2009). Long-Term Prognosis of Acute Kidney Injury after First Acute Stroke. CJASN 4: 616-622 [Abstract] [Full Text]  
• Hori, M., Nishida, K. (2009). Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc Res 81: 457-464 [Abstract] [Full Text]  
• Abrahamsson, P., Dobson, J., Granger, C. B., McMurray, J. J.V., Michelson, E. L., Pfeffer, M., Pocock, S., Solomon, S. D., Yusuf, S., Swedberg, K., for the CHARM Investigators, (2009). Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. Eur Heart J 30: 338-345 [Abstract] [Full Text]  
• Fried, L. F., Duckworth, W., Zhang, J. H., O'Connor, T., Brophy, M., Emanuele, N., Huang, G. D., McCullough, P. A., Palevsky, P. M., Seliger, S., Warren, S. R., Peduzzi, P., for VA NEPHRON-D Investigators, (2009). Design of Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D). CJASN 4: 361-368 [Abstract] [Full Text]  
• Meris, A., Amigoni, M., Uno, H., Thune, J. J., Verma, A., Kober, L., Bourgoun, M., McMurray, J. J., Velazquez, E. J., Maggioni, A. P., Ghali, J., Arnold, J. M. O., Zelenkofske, S., Pfeffer, M. A., Solomon, S. D. (2009). Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo Study. Eur Heart J 30: 56-65 [Abstract] [Full Text]  
• Tsagalis, G., Akrivos, T., Alevizaki, M., Manios, E., Stamatellopoulos, K., Laggouranis, A., Vemmos, K. N. (2009). Renal dysfunction in acute stroke: an independent predictor of long-term all combined vascular events and overall mortality. Nephrol Dial Transplant 24: 194-200 [Abstract] [Full Text]  
• Ishii, H., Amano, T., Matsubara, T., Murohara, T. (2008). Pharmacological Intervention for Prevention of Left Ventricular Remodeling and Improving Prognosis in Myocardial Infarction. Circulation 118: 2710-2718 [Full Text]  
• van den Borne, S. W.M., Isobe, S., Verjans, J. W., Petrov, A., Lovhaug, D., Li, P., Zandbergen, H. R., Ni, Y., Frederik, P., Zhou, J., Arbo, B., Rogstad, A., Cuthbertson, A., Chettibi, S., Reutelingsperger, C., Blankesteijn, W. M., Smits, J. F.M., Daemen, M. J.A.P., Zannad, F., Vannan, M. A., Narula, N., Pitt, B., Hofstra, L., Narula, J. (2008). Molecular Imaging of Interstitial Alterations in Remodeling Myocardium After Myocardial Infarction. J Am Coll Cardiol 52: 2017-2028 [Abstract] [Full Text]  
• Kaschina, E., Grzesiak, A., Li, J., Foryst-Ludwig, A., Timm, M., Rompe, F., Sommerfeld, M., Kemnitz, U. R., Curato, C., Namsolleck, P., Tschope, C., Hallberg, A., Alterman, M., Hucko, T., Paetsch, I., Dietrich, T., Schnackenburg, B., Graf, K., Dahlof, B., Kintscher, U., Unger, T., Steckelings, U. M. (2008). Angiotensin II Type 2 Receptor Stimulation: A Novel Option of Therapeutic Interference With the Renin-Angiotensin System in Myocardial Infarction?. Circulation 118: 2523-2532 [Abstract] [Full Text]  
• Authors/Task Force Members, , Van de Werf, F., Bax, J., Betriu, A., Blomstrom-Lundqvist, C., Crea, F., Falk, V., Filippatos, G., Fox, K., Huber, K., Kastrati, A., Rosengren, A., Steg, P. G., Tubaro, M., Verheugt, F., Weidinger, F., Weis, M., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., Document Reviewers, , Silber, S., Aguirre, F. V., Al-Attar, N., Alegria, E., Andreotti, F., Benzer, W., Breithardt, O., Danchin, N., Mario, C. D., Dudek, D., Gulba, D., Halvorsen, S., Kaufmann, P., Kornowski, R., Lip, G. Y. H., Rutten, F. (2008). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:. Eur Heart J 29: 2909-2945 [Full Text]  
• Knobloch, K., Bedair, H., Uehara, K., Fu, F. H., Huard, J. (2008). Letter to the Editor * Authors' Response. Am J Sports Med 36: e5-e7 [Full Text]  
• Velagaleti, R. S., Pencina, M. J., Murabito, J. M., Wang, T. J., Parikh, N. I., D'Agostino, R. B., Levy, D., Kannel, W. B., Vasan, R. S. (2008). Long-Term Trends in the Incidence of Heart Failure After Myocardial Infarction. Circulation 118: 2057-2062 [Abstract] [Full Text]  
• Ellmers, L. J., Scott, N. J. A., Medicherla, S., Pilbrow, A. P., Bridgman, P. G., Yandle, T. G., Richards, A. M., Protter, A. A., Cameron, V. A. (2008). Transforming Growth Factor-{beta} Blockade Down-Regulates the Renin-Angiotensin System and Modifies Cardiac Remodeling after Myocardial Infarction. Endocrinology 149: 5828-5834 [Abstract] [Full Text]  
• Ho, P. M., Peterson, P. N., Masoudi, F. A. (2008). Evaluating the Evidence: Is There a Rigid Hierarchy?. Circulation 118: 1675-1684 [Full Text]  
• Farkouh, M. E, Bansilal, S. (2008). Telmisartan and ramipril were equivalent, but their combination increased adverse events in vascular disease or diabetes. Evid. Based Med. 13: 147-147 [Full Text]  
• Authors/Task Force Members, , Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J. J.V., Ponikowski, P., Poole-Wilson, P. A., Stromberg, A., van Veldhuisen, D. J., Atar, D., Hoes, A. W., Keren, A., Mebazaa, A., Nieminen, M., Priori, S. G., Swedberg, K., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., Document Reviewers, , Tendera, M., Auricchio, A., Bax, J., Bohm, M., Corra, U., della Bella, P., Elliott, P. M., Follath, F., Gheorghiade, M., Hasin, Y., Hernborg, A., Jaarsma, T., Komajda, M., Kornowski, R., Piepoli, M., Prendergast, B., Tavazzi, L., Vachiery, J.-L., Verheugt, F. W. A., Zamorano, J. L., Zannad, F. (2008). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29: 2388-2442 [Full Text]  
• Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J. J.V., Ponikowski, P., Poole-Wilson, P. A., Stromberg, A., van Veldhuisen, D. J., Atar, D., Hoes, A. W., Keren, A., Mebazaa, A., Nieminen, M., Priori, S. G., Swedberg, K. (2008). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10: 933-989 [Full Text]  
• Verma, A., Meris, A., Skali, H., Ghali, J. K., Arnold, J. M. O., Bourgoun, M., Velazquez, E. J., McMurray, J. J.V., Kober, L., Pfeffer, M. A., Califf, R. M., Solomon, S. D. (2008). Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study.. J Am Coll Cardiol Img 1: 582-591 [Abstract] [Full Text]  
• Schindler, C. (2008). ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist`s perspective after publication of the results of ONTARGET. Ther Adv Cardiovasc Dis 2: 233-248 [Abstract]  
• Buchner, N., Banas, B., Kramer, B. K., Messerli, F. H., Bangalore, S., Ram, V. S., McMurray, J. J.V. (2008). Telmisartan, ramipril, or both in patients at high risk of vascular events.. NEJM 359: 426-427 [Full Text]  
• Triplitt, C., Alvarez, C. A. (2008). Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes. Diabetes Spectr. 21: 177-189 [Abstract] [Full Text]  
• Dimmeler, S., Leri, A. (2008). Aging and Disease as Modifiers of Efficacy of Cell Therapy. Circ. Res. 102: 1319-1330 [Abstract] [Full Text]  
• Werner, C. M., Bohm, M. (2008). Review: The therapeutic role of RAS blockade in chronic heart failure. Ther Adv Cardiovasc Dis 2: 167-177 [Abstract]  
• Cleland, J. G.F., Coletta, A. P., Yassin, A., Hado, H., Cullington, D., Abdellah, A. T., Clark, A. L. (2008). Clinical trials update from the American College of Cardiology 2008: Carisma, Trends, meta-analysis of Cox-2 studies, Hat, on-Target, Hyvet, Accomplish, Momentum, Protect, Horizon-hf and Reverse. Eur J Heart Fail 10: 614-620 [Abstract] [Full Text]  
• Prisant, L. M., Thomas, K. L., Lewis, E. F., Huang, Z., Francis, G. S., Weaver, W. D., Pfeffer, M. A., McMurray, J. J.V., Califf, R. M., Velazquez, E. J. (2008). Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both. J Am Coll Cardiol 51: 1865-1871 [Abstract] [Full Text]  
• Schocken, D. D., Benjamin, E. J., Fonarow, G. C., Krumholz, H. M., Levy, D., Mensah, G. A., Narula, J., Shor, E. S., Young, J. B., Hong, Y. (2008). Prevention of Heart Failure: A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 117: 2544-2565 [Abstract] [Full Text]  
• McMurray, J. J.V. (2008). ACE Inhibitors in Cardiovascular Disease -- Unbeatable?. NEJM 358: 1615-1616 [Full Text]  
• The ONTARGET Investigators, (2008). Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. NEJM 358: 1547-1559 [Abstract] [Full Text]  
• Albert, N. M., Lewis, C. (2008). Recognizing and Managing Asymptomatic Left Ventricular Dysfunction: After Myocardial Infarction. Crit Care Nurse 28: 20-37 [Full Text]  
• Setoguchi, S., Glynn, R. J., Avorn, J., Mittleman, M. A., Levin, R., Winkelmayer, W. C. (2008). Improvements in Long-Term Mortality After Myocardial Infarction and Increased Use of Cardiovascular Drugs After Discharge: A 10-Year Trend Analysis. J Am Coll Cardiol 51: 1247-1254 [Abstract] [Full Text]  
• Lewis, E. F., Velazquez, E. J., Solomon, S. D., Hellkamp, A. S., McMurray, J. J.V., Mathias, J., Rouleau, J.-L., Maggioni, A. P., Swedberg, K., Kober, L., White, H., Dalby, A. J., Francis, G. S., Zannad, F., Califf, R. M., Pfeffer, M. A. (2008). Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. Eur Heart J 29: 748-756 [Abstract] [Full Text]  
• Reynolds, H. R., Hochman, J. S. (2008). Cardiogenic Shock: Current Concepts and Improving Outcomes. Circulation 117: 686-697 [Full Text]  
• Nahrendorf, M., Aikawa, E., Figueiredo, J.-L., Stangenberg, L., van den Borne, S. W., Blankesteijn, W. M., Sosnovik, D. E., Jaffer, F. A., Tung, C.-H., Weissleder, R. (2008). Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction. Eur Heart J 29: 445-454 [Abstract] [Full Text]  
• Li, P., Kondo, T., Numaguchi, Y., Kobayashi, K., Aoki, M., Inoue, N., Okumura, K., Murohara, T. (2008). Role of Bradykinin, Nitric Oxide, and Angiotensin II Type 2 Receptor in Imidapril-Induced Angiogenesis. Hypertension 51: 252-258 [Abstract] [Full Text]  
• van Domburg, R. T., Hoeks, S. E., Welten, G. M.J.M., Chonchol, M., Elhendy, A., Poldermans, D. (2008). Renal Insufficiency and Mortality in Patients with Known or Suspected Coronary Artery Disease. J. Am. Soc. Nephrol. 19: 158-163 [Abstract] [Full Text]  
• Perticone, F., Maio, R., Sciacqua, A., Andreozzi, F., Iemma, G., Perticone, M., Zoccali, C., Sesti, G. (2008). Endothelial Dysfunction and C-Reactive Protein Are Risk Factors for Diabetes in Essential Hypertension. Diabetes 57: 167-171 [Abstract] [Full Text]  
• Thune, J. J., Signorovitch, J., Kober, L., Velazquez, E. J., McMurray, J. J.V., Califf, R. M., Maggioni, A. P., Rouleau, J. L., Howlett, J., Zelenkofske, S., Pfeffer, M. A., Solomon, S. D. (2008). Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction. Hypertension 51: 48-54 [Abstract] [Full Text]  
• Uresin, Y., Taylor, A. A, Kilo, C., Tschope, D., Santonastaso, M., Ibram, G., Hui Fang, , Satlin, A. (2007). Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. Journal of Renin-Angiotensin-Aldosterone System 8: 190-200 [Abstract]  
• Isbell, D. C., Voros, S., Yang, Z., DiMaria, J. M., Berr, S. S., French, B. A., Epstein, F. H., Bishop, S. P., Wang, H., Roy, R. J., Kemp, B. A., Matsubara, H., Carey, R. M., Kramer, C. M. (2007). Interaction between bradykinin subtype 2 and angiotensin II type 2 receptors during post-MI left ventricular remodeling. Am. J. Physiol. Heart Circ. Physiol. 293: H3372-H3378 [Abstract] [Full Text]  
• Beanlands, R. S.B., Nichol, G., Huszti, E., Humen, D., Racine, N., Freeman, M., Gulenchyn, K. Y., Garrard, L., deKemp, R., Guo, A., Ruddy, T. D., Benard, F., Lamy, A., Iwanochko, R. M., the PARR-2 Investigators{ddagger}{ddagger}, (2007). F-18-Fluorodeoxyglucose Positron Emission Tomography Imaging-Assisted Management of Patients With Severe Left Ventricular Dysfunction and Suspected Coronary Disease: A Randomized, Controlled Trial (PARR-2). J Am Coll Cardiol 50: 2002-2012 [Abstract] [Full Text]  
• Parikh, N. I., Gona, P., Larson, M. G., Wang, T. J., Newton-Cheh, C., Levy, D., Benjamin, E. J., Kannel, W. B., Vasan, R. S. (2007). Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study. Eur Heart J 28: 2644-2652 [Abstract] [Full Text]  
• Phillips, C. O., Kashani, A., Ko, D. K., Francis, G., Krumholz, H. M. (2007). Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction: A Quantitative Review of Data From Randomized Clinical Trials. Arch Intern Med 167: 1930-1936 [Abstract] [Full Text]  
• Jacquier, A., Higgins, C. B., Martin, A. J., Do, L., Saloner, D., Saeed, M. (2007). Injection of Adeno-associated Viral Vector Encoding Vascular Endothelial Growth Factor Gene in Infarcted Swine Myocardium: MR Measurements of Left Ventricular Function and Strain. Radiology 245: 196-205 [Abstract] [Full Text]  
• Verma, A., Anavekar, N. S., Meris, A., Thune, J. J., Arnold, J. M. O., Ghali, J. K., Velazquez, E. J., McMurray, J. J.V., Pfeffer, M. A., Solomon, S. D. (2007). The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis After Myocardial Infarction: The VALIANT Echo Study. J Am Coll Cardiol 50: 1238-1245 [Abstract] [Full Text]  
• Solomon, S. D., Dobson, J., Pocock, S., Skali, H., McMurray, J. J.V., Granger, C. B., Yusuf, S., Swedberg, K., Young, J. B., Michelson, E. L., Pfeffer, M. A., for the Candesartan in Heart failure: Assessment o, (2007). Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure. Circulation 116: 1482-1487 [Abstract] [Full Text]  
• Hall, A. S, Strauss, M. H (2007). More about the "ARB MI paradox". Heart 93: 1011-1014 [Abstract] [Full Text]  
• Azizi, M., Menard, J., Bissery, A., Guyene, T.-T., Bura-Riviere, A. (2007). Hormonal and Hemodynamic Effects of Aliskiren and Valsartan and Their Combination in Sodium-Replete Normotensive Individuals. CJASN 2: 947-955 [Abstract] [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: e1-e157 [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: 652-726 [Full Text]  
• Rosendorff, C., Black, H. R., Cannon, C. P., Gersh, B. J., Gore, J., Izzo, J. L. Jr, Kaplan, N. M., O'Connor, C. M., O'Gara, P. T., Oparil, S. (2007). REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Hypertension 50: e28-e55 [Full Text]  
• Schiffrin, E. L., Lipman, M. L., Mann, J. F.E. (2007). Chronic Kidney Disease: Effects on the Cardiovascular System. Circulation 116: 85-97 [Abstract] [Full Text]  
• Authors/Task Force Members, , Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A.A., Hasdai, D., Ohman, E. M., Wallentin, L., Wijns, W., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Kristensen, S. D., Widimsky, P., McGregor, K., Sechtem, U., Tendera, M., Hellemans, I., Gomez, J. L. Z., Silber, S., Funck-Brentano, C., Document Reviewers, , Kristensen, S. D., Andreotti, F., Benzer, W., Bertrand, M., Betriu, A., De Caterina, R., DeSutter, J., Falk, V., Ortiz, A. F., Gitt, A., Hasin, Y., Huber, K., Kornowski, R., Lopez-Sendon, J., Morais, J., Nordrehaug, J. E., Silber, S., Steg, P. G., Thygesen, K., Tubaro, M., Turpie, A. G.G., Verheugt, F., Windecker, S. (2007). Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 28: 1598-1660 [Full Text]  
• Kloner, R. A., Cannom, D. S. (2007). Uncertainty on the Use of Aldosterone Antagonists for Primary Therapy for Sudden Cardiac Death in the Setting of Implanted Devices. Circulation 115: 2983-2989 [Full Text]  
• Authors/Task Force Members:, , Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., Narkiewicz, K., Ruilope, L., Rynkiewicz, A., Schmieder, R. E., Struijker Boudier, H. A.J., Zanchetti, A., ESC Committee for Practice Guidelines (CPG):, , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., ESH Scientific Council:, , Kjeldsen, S. E., Erdine, S., Narkiewicz, K., Kiowski, W., Agabiti-Rosei, E., Ambrosioni, E., Cifkova, R., Dominiczak, A., Fagard, R., Heagerty, A. M., Laurent, S., Lindholm, L. H., Mancia, G., Manolis, A., Nilsson, P. M., Redon, J., Schmieder, R. E., Struijker-Boudier, H. A.J., Viigimaa, M., Document Reviewers:, , Filippatos, G., Adamopoulos, S., Agabiti-Rosei, E., Ambrosioni, E., Bertomeu, V., Clement, D., Erdine, S., Farsang, C., Gaita, D., Kiowski, W., Lip, G., Mallion, J.-M., Manolis, A. J., Nilsson, P. M., O'Brien, E., Ponikowski, P., Redon, J., Ruschitzka, F., Tamargo, J., van Zwieten, P., Viigimaa, M., Waeber, B., Williams, B., Zamorano, J. L. (2007). 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 0: ehm236v1-75 [Full Text]  
• Koh, K. K., Quon, M. J., Lee, Y., Han, S. H., Ahn, J. Y., Chung, W.-J., Kim, J.-a, Shin, E. K. (2007). Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients. Eur Heart J 28: 1440-1447 [Abstract] [Full Text]  
• Hennekens, C. H., Pfeffer, M. A., Swedberg, K. (2007). The CHARM Program: Study Design Leads to Findings of Clinical and Public Health Importance. J CARDIOVASC PHARMACOL THER 12: 124-126 [Abstract]  
• Delea, T. E., Taneja, C., Moynahan, A., Thomas, S. K., Frech-Tamas, F., Oster, G. (2007). Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension. Am J Health Syst Pharm 64: 1187-1196 [Abstract] [Full Text]